MedTrace Logo

Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover

NCT01249261 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2011-11-02

Study results available
· View outcomes & findings →

Summary

The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

DRUG

Risedronate

5 mg/day

DRUG

Placebo/Risedronate

placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8

Sponsors & Collaborators

  • Warner Chilcott

    lead INDUSTRY

Principal Investigators

  • Herman Ellman, MD · Warner Chilcott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2003-05-31
Completion
2003-05-31

Countries

  • Australia
  • Belgium
  • Denmark
  • Finland
  • Italy
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01249261 on ClinicalTrials.gov